"Advancements in Sickle Cell Gene Therapies Offer Hope for Patients"
TL;DR Summary
The U.S. government plans to implement an "access model" to help state Medicaid programs afford new gene therapies for sickle cell disease, which come with multimillion-dollar price tags. The Centers for Medicare and Medicaid Services will pursue outcomes-based agreements with drug manufacturers to negotiate pricing and rebates on behalf of participating states, starting in January 2025. This move aims to alleviate concerns over the financial burden of these curative treatments on Medicaid programs, which many people with sickle cell disease rely on for health care coverage.
Topics:business#centers-for-medicare-and-medicaid-services#gene-therapies#healthcare#medicaid#outcomes-based-agreements#sickle-cell-disease
- Medicaid announces plan for expensive sickle cell gene therapies STAT
- New FDA-approved sickle cell gene editing therapies offer hope for a pain-free life to patients – some living in Colorado Colorado Public Radio
- Biden-Harris Administration Announces Action to Increase Access to Sickle Cell Disease Treatments HHS.gov
- CMS: Cell and gene therapy model to focus first on sickle cell treatments FierceHealthcare
- Science for Living: Scot Wolfe explains revolutionary CRISPR gene-editing treatment UMass Medical School
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
57%
202 → 86 words
Want the full story? Read the original article
Read on STAT